Miscellaneous

2020 – Review of Clinical Application of Radiation Enhancing Nanoparticles

The two main NP used in clinical trials were hafnium oxide and gadolinium involving a total of 229 patients. Hafnium oxide NP were used in three phase 1/2 trials on sarcoma, head and neck squamous cell carcinoma or liver cancer and one phase 2/3 trial. There are six ongoing phase 1/2 clinical trials to evaluate the combination of gadolinium-based NP and RT for the treatment of brain metastases and cervical cancer. […]

2019 – Bulletin Cancer – NBTXR3 improves pathological response

Miscellaneous, NO-RIGHTS, Publications

Doubling complete histological response in sarcomas with radiation therapy using nanoparticles (Hafnium oxide, NBTXR3), a phase III trial.

2017 – Nano-sized cytochrome p450 3a4 inhibitors to block hepatic – Paolini et al.

Miscellaneous, NO-RIGHTS, Publications

Most drugs are metabolized by hepatic cytochrome P450 3A4 (CYP3A4), resulting in their reduced bioavailability. In this study, we present the design and evaluation of biocompatible nanocarriers trapping a natural CYP3A4-inhibiting compound. Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic CYP3A4 and leave drug-metabolizing enzymes in other organs undisturbed.

2017 – A new opportunity for nanomedicines – Paolini et al.

Miscellaneous, NO-RIGHTS, Publications

Nanomedicines are mainly used as drug delivery systems; here we evaluate a new application - to inhibit a drug's metabolism thereby enhancing its effective dose. Micelles containing the natural furanocoumarin 6′,7′ dihydroxybergamottin (DHB), a known CYP450 inhibitor, were developed to transiently block hepatic CYP450-mediated drug metabolism and increase the bioavailability of the oncology drug docetaxel.

2015 – Metals as radio-enhancers in oncology – Pottier et al.

Miscellaneous, NO-RIGHTS, Publications

Radio-enhancers, metal-based nanosized agents, could play a key role in oncology. They may unlock the potential of radiotherapy by enhancing the radiation dose deposit within tumors when the ionizing radiation source is ‘on’, while exhibiting chemically inert behavior in cellular and subcellular systems when the radiation beam is ‘off’. Important decision points support the development of these new type of therapeutic agents originated from nanotechnology. Here, we discuss from an industry perspective, the interest of developing radio-enhancer agents to improve tumor control, the relevance of nanotechnology to achieve adequate therapeutic attributes, and present some considerations for their development in oncology.

2015 – The future of nanosized radiation enhancers – Pottier et al.

Miscellaneous, NO-RIGHTS, Publications

Radiotherapy has a universal and predictable mode of action, that is, a physical mode of action consisting of the deposit of a dose of energy in tissues. Tumour cell damage is proportional to the energy dose. However, the main limitation of radiotherapy is the lack of spatial control of the deposition of energy, that is, it penetrates the healthy tissues, damages them and renders unfeasible delivery of an efficient energy dose when tumours are close to important anatomical structures. True nanosized radiation enhancers may represent a disruptive approach to broaden the therapeutic window of radiation therapy.

2010 – Concept of NBTXR3 – Borghi et al.

Miscellaneous, NO-RIGHTS, Publications

La nanotechnologie permet une gestion et un assemblage de matériaux sans précédent dans l’histoire des produits utilisés en santé humaine. Cette révolution est apportée par la possibilité d’utiliser de nouveaux mécanismes thérapeutiques et de dissocier les différentes fonctions de la substance médicamenteuse (distribution, effet thérapeutique…), ce qui était jusqu’ici impossible avec les médicaments classiques.

2010 – Nanocarrier for Photodynamic Therapy – Thienot et al.

Miscellaneous, NO-RIGHTS, Publications

A new versatile hybrid nano carrier has been designed using a “soft chemistry” synthesis, to efficiently encapsulate a photosensitizer – the protoporphyrin IX (Pp IX) – while preserving its activity intact in biological environment for advantageous use in photodynamic therapy (PDT).

2010 – Silica Nanoparticles – Simon et al.

Miscellaneous, NO-RIGHTS, Publications

Protoporphyrin IX (Pp IX) silica nanoparticles, developed for effective use in photodynamic therapy (PDT), were explored in in vitro and in vivo models with the ambition to improve knowledge on the role of biological factors in the photodamage. Pp IX silica nanoparticles are found efficient at temperature with extreme metabolic downregulation, which suggest a high proportion of passive internalization. For the first time, clearance of silica nanoparticles on tumor cells is established. Cell viability assessment in six tumor cell lines is reported.

2010 – Combinations of proteins with Nano-Systems – Di Marco et al.

Miscellaneous, NO-RIGHTS, Publications

The latest development of protein engineering allows the production of proteins having desired properties and large potential markets, but the clinical advances of therapeutical proteins are still limited by their fragility. Nanotechnology could provide optimal vectors able to protect from degradation therapeutical biomolecules such as proteins, enzymes or specific polypeptides.

In this section publications of Nanobiotix can be found which are related to Nanobiotix other technologies or specific research projects.